CEO Letter: A Moment of Transition for CS MEDICA

Dear Shareholders, Partners, and Supporters,

As we approach the delisting of CS MEDICA from the Spotlight Stock Market on January 9, 2025, EOB we find ourselves at a pivotal moment, albeit not one of our choosing. This transition marks a challenging time for our company and shareholders, but it also offers an opportunity to realign and build resilience.

Over the past two weeks, since receiving the notification from Spotlight, we have navigated a challenging landscape. Despite the holiday season, our efforts have been persistent, as have our stakeholders. We have engaged with close shareholders, consulted experts with proven track records in delisting, relisting, and restructuring, and gained valuable insights from companies that have undergone similar transitions. Additionally, we have drawn the interest of new cornerstone investors and venture partners who view this shift as a strategic move to prioritize growth and pave the way for a future listing on a more suitable trading platform.

We are grateful for the support from our stakeholders. This challenging period has been a source of frustration but also renewed motivation, reaffirming our confidence in the unique value of our products and solutions that continue to gain recognition from both partners and competitors.
 

During this challenging period, we have reached the following decisions and milestones:

1. Focus on the Business: To optimize our business case over the next six months, we are temporarily halting all activities that do not deliver short-term revenue or is already in progress, as i.e. registrations co-funded by partners. This strategy enables us to focus on initiatives that drive immediate financial results and strengthen our foundation for sustainable growth.
2. New White-Label Order Secured: We finalized a 1.1 million DKK deal in Italy, marking a crucial step in our market expansion.
3. Progress in China: The first part of a redefined Investment agreement, total 1.15 million DKK, has successfully been transferred by RongShi to its legal representative in Denmark, enabling us to activate the next phase of our Investment agreement.
4. Malaysia Registration: RongShi has paid the latest registration fee in Malaysia, and we have received confirmation of product registration for our flagship product, the Pain & Arthritis Gel. This opens the door for Joint Venture sales in this market and cross-border opportunities in other Asian regions.
5. India On Hold: We are fully prepared to initiate final registrations and production in India. However, we will proceed once local funding is secured to ensure focus and sustainable growth.
6. Planned IPO in Germany: We received feedback this week from BaFin regarding our planned IPO in Germany. While we are progressing, a strong pre-sale is crucial to securing an upside that justifies the IPO investment. We are moving forward with this in mind, leveraging lessons learned from the Spotlight listing.
7. New Investors and Advisors: We are onboarding new investors as advisors with proven track records to support our journey and ensure continued progress.

This period of change reinforces our commitment to delivering innovative and effective CBD-infused medical devices that enhance lives. We remain steadfast in our mission to drive growth while maintaining compliance with the strict MDR regulatory framework—a position that uniquely distinguishes us within the MedTech industry.

Stakeholders are encouraged to stay updated by signing up for the newsletter at cs-medica.com, or through reliable channels like Cision News.

For further details on the delisting process and future company communication, please refer to our previous press release.

Sincerely,

Board of Directors & Management team

CS MEDICA A/S

 

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
 

CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally. The company has been listed at Spotlight Stock Market in Stockholm (symbol: “CSMED”) from September 2021 to 9.1.2025. 

Tags: